港股異動 | 復星醫藥A+H聯袂上漲 所合作的BioNTech開始進行新冠疫苗人體試驗
格隆匯4月23日丨復星醫藥(2196.HK)今日高開高走,現漲5%,報30.45港元,創逾一年新高,總市值780.4億港元;復星醫藥(600196.SH)亦漲近2%,股價創2018年7月26日以來最高。復星醫藥3月中旬獲德國生物技術商BioNTech許可,於其mRNA技術平台研發針對新冠肺炎疫苗產品,同時復星醫藥以每股31.63美元,認購BioNTech發行158.1萬股普通股,涉及金額約5000萬美元。BioNTech SE和輝瑞公佈,德國監管機構已經批准兩公司聯合開發的BNT162新冠疫苗項目進入第1/2階段臨牀試驗,為德國首個獲批進入人體臨牀試驗的新冠疫苗。BioNTech預計將在中國與復星醫藥合作商業化該疫苗,BioNTech隔晚法蘭克福一度飆升63%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.